MARKET

GMAB

GMAB

Genmab
NASDAQ
26.55
-0.54
-1.99%
Pre Market: 26.55 0 0.00% 07:42 05/14 EDT
OPEN
26.53
PREV CLOSE
27.09
HIGH
26.78
LOW
26.33
VOLUME
41
TURNOVER
0
52 WEEK HIGH
35.43
52 WEEK LOW
18.89
MARKET CAP
17.06B
P/E (TTM)
20.11
1D
5D
1M
3M
1Y
5Y
1D
Genmab Updates Articles of Association, Expands Capital and Incentive Authorizations
TipRanks · 21h ago
Genmab Announces Minor Capital Increase Following Employee Warrant Exercise
TipRanks · 1d ago
Genmab issued share capital totals 62,353,067 shares, voting rights match after increase
PUBT · 1d ago
Genmab issues 2,346 shares after employee warrant exercise, raising about DKK 3 million
PUBT · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Genmab (GMAB), Caris Life Sciences, Inc. (CAI)
TipRanks · 2d ago
Genmab price target lowered to DKK 2,250 from DKK 2,400 at Deutsche Bank
TipRanks · 2d ago
Weekly Report: what happened at GMAB last week (0504-0508)?
Weekly Report · 3d ago
Genmab A/S (0MGB) Receives a Buy from Goldman Sachs
TipRanks · 4d ago
More
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Webull offers Genmab A/S - ADR stock information, including NASDAQ: GMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GMAB stock methods without spending real money on the virtual paper trading platform.